Metsera (NASDAQ:MTSR) Trading Down 12.6% - Should You Sell?

Metsera, Inc. (NASDAQ:MTSR - Get Free Report) fell 12.6% during trading on Wednesday . The company traded as low as $12.40 and last traded at $12.42. 285,175 shares changed hands during mid-day trading, a decline of 62% from the average session volume of 747,144 shares. The stock had previously closed at $14.21.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Cantor Fitzgerald initiated coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued an "overweight" rating for the company. Guggenheim initiated coverage on Metsera in a research note on Tuesday, February 25th. They issued a "buy" rating and a $56.00 price objective on the stock. Bank of America initiated coverage on Metsera in a research report on Tuesday, February 25th. They set a "buy" rating and a $38.00 target price for the company. Finally, Evercore ISI started coverage on Metsera in a research note on Tuesday, February 25th. They set an "outperform" rating on the stock.

Metsera Stock Performance

The stock has a 50 day moving average of $25.74.

Metsera (NASDAQ:MTSR - Get Free Report) last issued its quarterly earnings data on Wednesday, March 26th. The company reported ($3.52) earnings per share for the quarter.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.